Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 170 of 170 entries
Sorted by: Best Match Show Resources per page
IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial.

Pediatric neurology

Dabrowski E, Chambers HG, Gaebler-Spira D, Banach M, Kaňovský P, Dersch H, Althaus M, Geister TL, Heinen F.
PMID: 34339951
Pediatr Neurol. 2021 Oct;123:10-20. doi: 10.1016/j.pediatrneurol.2021.05.014. Epub 2021 May 21.

BACKGROUND: This randomized phase 3 study with double-blind main period (MP) and open-label extension (OLEX; NCT02002884) assessed incobotulinumtoxinA safety and efficacy for pediatric upper-limb spasticity treatment in ambulant/nonambulant (Gross Motor Function Classification System [GMFCS] I-V) patients, with the option...

Cite
Dabrowski E, Chambers HG, Gaebler-Spira D, et al. IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatr Neurol. 2021;123:10-20doi: 10.1016/j.pediatrneurol.2021.05.014.
Dabrowski, E., Chambers, H. G., Gaebler-Spira, D., Banach, M., Kaňovský, P., Dersch, H., Althaus, M., Geister, T. L., & Heinen, F. (2021). IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatric neurology, 12310-20. https://doi.org/10.1016/j.pediatrneurol.2021.05.014
Dabrowski, Edward, et al. "IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial." Pediatric neurology vol. 123 (2021): 10-20. doi: https://doi.org/10.1016/j.pediatrneurol.2021.05.014
Dabrowski E, Chambers HG, Gaebler-Spira D, Banach M, Kaňovský P, Dersch H, Althaus M, Geister TL, Heinen F. IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in Pediatric Cerebral Palsy: Randomized Controlled Trial. Pediatr Neurol. 2021 Oct;123:10-20. doi: 10.1016/j.pediatrneurol.2021.05.014. Epub 2021 May 21. PMID: 34339951.
Copy Download .nbib Format: NLM
The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial.

Trials

Zügel M, Bizjak DA, Nussbaumer D, Winkert K, Takabayashi K, Kirsten J, Washington M, Treff G, Dreyhaupt J, Steeb L, Diel P, Parr MK, Steinacker JM, Persch H.
PMID: 34895300
Trials. 2021 Dec 11;22(1):903. doi: 10.1186/s13063-021-05862-w.

BACKGROUND: Asthma and/or airway hyper-responsiveness (AHR) are common in elite endurance athletes with a high prevalence rate of beta-2 adrenoreceptor (beta-2) agonists use. Nevertheless, there are data on dose-dependent ergogenic effects of beta-2 agonists suggesting increased muscle strength, endurance...

Cite
Zügel M, Bizjak DA, Nussbaumer D, et al. The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial. Trials. 2021;22(1):903doi: 10.1186/s13063-021-05862-w.
Zügel, M., Bizjak, D. A., Nussbaumer, D., Winkert, K., Takabayashi, K., Kirsten, J., Washington, M., Treff, G., Dreyhaupt, J., Steeb, L., Diel, P., Parr, M. K., Steinacker, J. M., & Persch, H. (2021). The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial. Trials, 22(1), 903. https://doi.org/10.1186/s13063-021-05862-w
Zügel, Martina, et al. "The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial." Trials vol. 22,1 (2021): 903. doi: https://doi.org/10.1186/s13063-021-05862-w
Zügel M, Bizjak DA, Nussbaumer D, Winkert K, Takabayashi K, Kirsten J, Washington M, Treff G, Dreyhaupt J, Steeb L, Diel P, Parr MK, Steinacker JM, Persch H. The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial. Trials. 2021 Dec 11;22(1):903. doi: 10.1186/s13063-021-05862-w. PMID: 34895300.
Copy Download .nbib Format: NLM
Showing 169 to 170 of 170 entries